Introduction：Basic information about CAS 145375-43-5|Mitiglinide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Mitiglinide |
|---|
| CAS Number | 145375-43-5 | Molecular Weight | 315.41 |
|---|
| Density | 1.2±0.1 g/cm3 | Boiling Point | 519.6±43.0 °C at 760 mmHg |
|---|
| Molecular Formula | C19H25NO3 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 268.0±28.2 °C |
|---|
Names
| Name | [2(S)-cis]-Octahydro-γ-oxo-α-(phenylmethyl)-2H-isoindole-2-butanoic acid |
|---|
| Synonym | More Synonyms |
|---|
Mitiglinide BiologicalActivity
| Description | Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2]. |
|---|
| Related Catalog | Research Areas >>Metabolic DiseaseSignaling Pathways >>Membrane Transporter/Ion Channel >>Potassium Channel |
|---|
| Target | KATP channel[1] |
|---|
| In Vitro | Mitiglinide inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 of 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 μM) in COS-1 cells[1]. |
|---|
| In Vivo | Mitiglinide (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load[2]. Animal Model: Pregnant Wistar rats (12 weeks)[2] Dosage: 0.3 mg/kg, 1 mg/kg, 3 mg/kg Administration: Oral administration Result: Dose-dependently suppressed AUCglucose levels. |
|---|
| References | [1]. Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431(1):119-25. [2]. Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29(5-6):423-7. |
|---|
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|
| Boiling Point | 519.6±43.0 °C at 760 mmHg |
|---|
| Molecular Formula | C19H25NO3 |
|---|
| Molecular Weight | 315.41 |
|---|
| Flash Point | 268.0±28.2 °C |
|---|
| Exact Mass | 315.183441 |
|---|
| PSA | 57.61000 |
|---|
| LogP | 4.73 |
|---|
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
|---|
| Index of Refraction | 1.567 |
|---|
| InChIKey | WPGGHFDDFPHPOB-BBWFWOEESA-N |
|---|
| SMILES | O=C(O)C(CC(=O)N1CC2CCCCC2C1)Cc1ccccc1 |
|---|
Safety Information
Customs
Synonyms
| Mitiglinide |
| Unii-D86I0xlb13 |
| (-)-(2S,3a,7a-cis)-α-Benzylhexahydro-γ-oxo-2-isoindolinebutyric acid |
| (2S)-2-Benzyl-4-((3a,7a-cis)-octahydro-2H-isoindol-2-yl)-4-oxobutanoic Acid |
| (-)-(2S,3a,7a-cis)-a-Benzylhexahydro-g-oxo-2-isoindolinebutyric Acid |
| (2S)-2-Benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol-2-yl]-4-oxobutanoic acid |
| 2H-Isoindole-2-butanoic acid, octahydro-γ-oxo-α-(phenylmethyl)-, (αS,3aR,7aS)- |
